P-170 Understanding patient experience in hepatocellular carcinoma: A qualitative patient interview study

Abstract

The incidence of G1-G2 and G3-G4 ematologic AEs was 36.4% and 4.4% for Bev-CT and 59.2% and 10.2% for Afli-CT, respectively. The incidence of G1-G2 and G3-G4 non class-specific and non-ematologic AEs was 36.4% and 4.4% for Bev-CT and 59.2% and 10.2% for Afli-CT, respectively. Conclusion:This study shows no differences in efficacy and activity between Bev-CT and Afli-CT, with a slightly higher incidence of class-specific, hematologic and nonclass-specific, non-hematologic AEs for Afli-CT compared to Bev-CT. Further analyses with larger sample size and a prospective design are certainly needed to better define and personalize the antiangiogenic strategy as second-line treatment in WT mCRC.Legal entity responsible for the study: The author.